![]() Program participants receive a certificate of completion from the Department of Labor at the end of the program. Apprentices receive a combination of paid on-the-job training while studying towards their associates degree, fully-funded by the program. Kite’s cell therapy apprenticeship is a two-to-four-year long program that provides qualified students with the opportunity to jumpstart a biotech career while pursuing a college education. In addition to Kite’s participation in Frederick Community College’s (FCC) highly successful Biotech Bootcamp, the company has also partnered with FCC and the Maryland Department of Labor to create a Cell Therapy Apprenticeship Program. Frederick Community College’s Cell Therapy Apprenticeship Program Kite’s new local workforce development partnerships aim to expand the talent pool and include Frederick Community College, Hood College in Frederick, Maryland, and the Workforce Taskforce. RELATED: Diversity, Equity & Inclusion at Kite a Key Facet of Frederick Manufacturing Site’s Work Culture It’s so important to grow talent organically and for Kite to work with local biotech training programs at colleges, community colleges and other organizations where students can learn the theoretical and unique operational aspects of working at a facility like ours,” stated Trushar Agrawal, Senior Director, Head of Manufacturing at Kite’s Frederick facility. “The demand for CAR T-cell therapy is growing and we will need new talent to support production so patients can receive their treatments rapidly and reliably. As the BHCR adds more and more companies in cell and gene therapy, medtech, and traditional biopharma, the pool of talent to support this growth will need to add depth, breadth, and diversity as well. Maryland already has a solid workforce development infrastructure in place with programs like BioTrain and Bio-Trac at Montgomery College Frederick Community College’s Biotech Bootcamp program The Biomedical Careers Program (BCI) and the Maryland Technology Internship Program (MTIP) at Johns Hopkins School of Medicine and Kite’s very own Early Talent Program.īut there is always a need for more targeted and robust workforce programming to support a biocluster region that’s growing by leaps and bounds every year. This ongoing, long-term commitment is a win-win for Kite and the community investing in workforce programs will support Kite’s plans to attract, retain and develop talent and the community and economy will benefit from the 400 plus jobs Kite will bring to the state by the end of 2022. Kite’s goal is to augment existing workforce development programming and to help the region continue building a thriving life sciences workforce. Kite has committed to building strong partnerships with the local community across an array of key constituencies, including workforce development initiatives at local universities and life sciences support organizations. ![]() The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer.Kite’s choice to plant roots in Maryland has been a boon to the economy and the region’s life sciences ecosystem. As a vital part of Gilead - a founding member of the Foundation for the NIH’s Partnership for Accelerating Cancer Therapies - we are devoted to advancing the understanding of cell therapy as a transformational treatment option for cancer. ![]() Since our acquisition by biopharma leader Gilead Sciences in October 2017, our combined strength has accelerated the advancement of our pipeline, including the launch of YESCARTA® (axicabtagene ciloleucel) and TECARTUS® (brexucabtagene autoleucel), and has expanded the impact of our strategic partnerships.Īs an independent operating company since 2019, we prioritize innovative R&D with the full resources, capabilities, and trust of Gilead. OUR STORY A SINGULAR FOCUS ON CELL THERAPYįounded in 2009 as a pioneer in cell therapy research, Kite’s leadership position in the immuno-oncology space was solidified with our research and development agreement with the National Cancer Institute in 2012 and when our commercial manufacturing site opened in El Segundo in 2016. Our industry-leading cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells. We believe cell therapy has the ability to change the way cancer is treated. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. OUR MISSION TRANSFORMATIONAL CANCER TREATMENTĪt Kite, our singular focus is cell therapy to treat and potentially cure cancer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |